BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 31018945)

  • 1. Increased RNA Expression of von Willebrand Factor Gene Is Associated With Infiltrating Lobular Breast Cancer and Normal PAM50 Subtype.
    Lehrer S; Green S; Dembitzer FR; Rheinstein PH; Rosenzweig KE
    Cancer Genomics Proteomics; 2019; 16(3):147-153. PubMed ID: 31018945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ERBB2 mutation is associated with a worse prognosis in patients with CDH1 altered invasive lobular cancer of the breast.
    Ping Z; Siegal GP; Harada S; Eltoum IE; Youssef M; Shen T; He J; Huang Y; Chen D; Li Y; Bland KI; Chang HR; Shen D
    Oncotarget; 2016 Dec; 7(49):80655-80663. PubMed ID: 27811364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of Stromal Tumor-infiltrating Lymphocytes and Genomic Alterations in Metastatic Lobular Breast Cancer.
    Richard F; Majjaj S; Venet D; Rothé F; Pingitore J; Boeckx B; Marchio C; Clatot F; Bertucci F; Mariani O; Galant C; Eynden GVD; Salgado R; Biganzoli E; Lambrechts D; Vincent-Salomon A; Pruneri G; Larsimont D; Sotiriou C; Desmedt C
    Clin Cancer Res; 2020 Dec; 26(23):6254-6265. PubMed ID: 32943456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis.
    Thorat MA; Marchio C; Morimiya A; Savage K; Nakshatri H; Reis-Filho JS; Badve S
    J Clin Pathol; 2008 Mar; 61(3):327-32. PubMed ID: 18037662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER2-Positive Lobular Versus Ductal Carcinoma of the Breast: Pattern of First Recurrence and Molecular Insights.
    Da Ros L; Moretti A; Querzoli P; Pedriali M; Lupini L; Bassi C; Carcoforo P; Negrini M; Frassoldati A
    Clin Breast Cancer; 2018 Oct; 18(5):e1133-e1139. PubMed ID: 29759595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Germline Pathogenic Variants in Cancer Predisposition Genes Among Women With Invasive Lobular Carcinoma of the Breast.
    Yadav S; Hu C; Nathanson KL; Weitzel JN; Goldgar DE; Kraft P; Gnanaolivu RD; Na J; Huang H; Boddicker NJ; Larson N; Gao C; Yao S; Weinberg C; Vachon CM; Trentham-Dietz A; Taylor JA; Sandler DR; Patel A; Palmer JR; Olson JE; Neuhausen S; Martinez E; Lindstrom S; Lacey JV; Kurian AW; John EM; Haiman C; Bernstein L; Auer PW; Anton-Culver H; Ambrosone CB; Karam R; Chao E; Yussuf A; Pesaran T; Dolinsky JS; Hart SN; LaDuca H; Polley EC; Domchek SM; Couch FJ
    J Clin Oncol; 2021 Dec; 39(35):3918-3926. PubMed ID: 34672684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer.
    Ciriello G; Gatza ML; Beck AH; Wilkerson MD; Rhie SK; Pastore A; Zhang H; McLellan M; Yau C; Kandoth C; Bowlby R; Shen H; Hayat S; Fieldhouse R; Lester SC; Tse GM; Factor RE; Collins LC; Allison KH; Chen YY; Jensen K; Johnson NB; Oesterreich S; Mills GB; Cherniack AD; Robertson G; Benz C; Sander C; Laird PW; Hoadley KA; King TA; ; Perou CM
    Cell; 2015 Oct; 163(2):506-19. PubMed ID: 26451490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis.
    Turashvili G; Bouchal J; Baumforth K; Wei W; Dziechciarkova M; Ehrmann J; Klein J; Fridman E; Skarda J; Srovnal J; Hajduch M; Murray P; Kolar Z
    BMC Cancer; 2007 Mar; 7():55. PubMed ID: 17389037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenomic and Transcriptomic Characterization of Secondary Breast Cancers.
    Graff-Baker AN; Orozco JIJ; Marzese DM; Salomon MP; Hoon DSB; Goldfarb M
    Ann Surg Oncol; 2018 Oct; 25(10):3082-3087. PubMed ID: 29956094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A high-risk luminal A dominant breast cancer subtype with increased mobility.
    Guo L; Chen G; Zhang W; Zhou L; Xiao T; Di X; Wang Y; Feng L; Zhang K
    Breast Cancer Res Treat; 2019 Jun; 175(2):459-472. PubMed ID: 30778902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Analysis of Oncotype DX Recurrence Scores and Clinicopathologic Characteristics in Invasive Lobular Breast Cancer.
    Felts JL; Zhu J; Han B; Smith SJ; Truica CI
    Breast J; 2017 Nov; 23(6):677-686. PubMed ID: 28097781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strong adverse effect of epidermal growth factor receptor 2 overexpression on prognosis of patients with invasive lobular breast cancer: a comparative study with invasive ductal breast cancer in Chinese population.
    Wang T; Ma Y; Wang L; Liu H; Chen M; Niu R
    Tumour Biol; 2015 Aug; 36(8):6113-24. PubMed ID: 25804795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced mRNA expression levels of NFE2L2 are associated with poor outcome in breast cancer patients.
    Wolf B; Goebel G; Hackl H; Fiegl H
    BMC Cancer; 2016 Oct; 16(1):821. PubMed ID: 27770790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relapsed classic E-cadherin (CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutations.
    Ross JS; Wang K; Sheehan CE; Boguniewicz AB; Otto G; Downing SR; Sun J; He J; Curran JA; Ali S; Yelensky R; Lipson D; Palmer G; Miller VA; Stephens PJ
    Clin Cancer Res; 2013 May; 19(10):2668-76. PubMed ID: 23575477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor suppressor PTEN in breast cancer: heterozygosity, mutations and protein expression.
    Kechagioglou P; Papi RM; Provatopoulou X; Kalogera E; Papadimitriou E; Grigoropoulos P; Nonni A; Zografos G; Kyriakidis DA; Gounaris A
    Anticancer Res; 2014 Mar; 34(3):1387-400. PubMed ID: 24596386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of clinical outcomes between luminal invasive ductal carcinoma and luminal invasive lobular carcinoma.
    Adachi Y; Ishiguro J; Kotani H; Hisada T; Ichikawa M; Gondo N; Yoshimura A; Kondo N; Hattori M; Sawaki M; Fujita T; Kikumori T; Yatabe Y; Kodera Y; Iwata H
    BMC Cancer; 2016 Mar; 16():248. PubMed ID: 27015895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
    Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
    Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer.
    Inoue M; Nakagomi H; Nakada H; Furuya K; Ikegame K; Watanabe H; Omata M; Oyama T
    Breast Cancer; 2017 Sep; 24(5):667-672. PubMed ID: 28108967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-Cell Transcriptomic Heterogeneity in Invasive Ductal and Lobular Breast Cancer Cells.
    Chen F; Ding K; Priedigkeit N; Elangovan A; Levine KM; Carleton N; Savariau L; Atkinson JM; Oesterreich S; Lee AV
    Cancer Res; 2021 Jan; 81(2):268-281. PubMed ID: 33148662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phylogenetic analysis of combined lobular and ductal carcinoma of the breast.
    Kobayashi H; Nakai T; Nakanishi Y; Esumi M; Masuda S
    Mol Med Rep; 2021 Oct; 24(4):. PubMed ID: 34396426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.